Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 471 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR A Rare Childbirth Complication Wiped This Woman’s Memory Of Giving Birth... December 4, 2019 Cancer in My Community: Working to Expand Access to Clinical Trials... September 22, 2022 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 Kid Friendly Meals October 2, 2020 Load more HOT NEWS Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow What’s happened to cancer services during the COVID-19 pandemic? Stem cell research: meet the scientist growing ‘mini guts’ in her... EMA Recommends Granting a Marketing Authorisation for Vorasidenib
